|
|
| Model Number |
MCP493G |
| Medical Device Problem Code |
Break (1069)
|
| Health Effect - Clinical Code |
No Clinical Signs, Symptoms or Conditions (4582)
|
| Date of Event |
07/21/2022
|
|
Type of Reportable Event
|
Malfunction
|
|
Additional Manufacturer Narrative
|
|
(b)(4).This report is being submitted pursuant to the provisions of 21 cfr, part 803, subpart b.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon inc, or its employees that the report constitutes an admission that the product, ethicon inc or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.A manufacturing record evaluation was performed for the finished device lot, and no non-conformances were identified.Additional information was requested, and the following was obtained: patient 5: was there any adverse consequence associated with the patient? no adverse event device return status: will wait for a box from ethicon to safely send back broken sutures.Attempts have been made to retrieve the device.To date the device has not been returned.If the device or further details are received at a later date a supplemental medwatch will be sent this is a combination product, and the event has been reviewed for both the suture and the triclosan.Trade name - irgacare active ingredient(s)- triclosan dosage form - suture/solid/parenteral strength - = 2360 g /m.
|
| |
|
Event or Problem Description
|
|
It was reported that a patient underwent an unknown procedure on (b)(6) 2022 and suture was used.During the procedure, the suture wasn't tied.The suture was used on skin.The suture was initially placed interrupted.Breakage occurred during the first pass through tissue.The approximate location of suture breakage was six inches in relation to needle.The suture did break in two pieces.Additional information was requested.
|
| |
|
Additional Manufacturer Narrative
|
|
Product complaint # (b)(4).Date sent to the fda: 9/15/2022 this is a combination product, and the event has been reviewed for both the suture and the triclosan.This report is being submitted pursuant to the provisions of 21 cfr, part 803, part 4 subpart b.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.H3 investigational summary: the product was returned to ethicon for evaluation.Visual inspection evaluation was conducted on the returned device.Visual analysis of the returned sample determined that one empty opened foil and one needle-suture piece product code mcp493g were returned for analysis.In order to evaluate the conditions of the returned sample, the suture piece was observed with body fluids and the end was broken after further evaluation crimping marks were observed on the surface suture possibly caused by a surgical instrument.As per returned conditions of the sample no functional test was performed.The condition of the sample received indicates improper handling of the device.As with any device, care should be taken to avoid damage to the strand when handling.Avoid the crushing or crimping action of the surgical instruments, such as needle holders and forceps.As part of our quality process, the manufacturing records of this lot-serial number were reviewed, and the manufacturing standards were met prior to the release of this batch.As part of ethicon quality process, all devices are manufactured, inspected, and released to approved specifications.Additional complaint information monitoring for potential safety signals is conducted through complaint trending as part of post-market surveillance.Trade name - irgacare® active ingredient(s) ¿ triclosan dosage form ¿ suture/solid/parenteral strength ¿ = 2360 g/m.
|
| |
|
Search Alerts/Recalls
|
|
|